ECM1 regulates tumor metastasis and CSC-like property through stabilization of β-catenin

Oncogene

Volumn 34, Issue 50, 2015, Pages 6055-6065

  Lee, K M ^a   Nam, K ^a   Oh, S ^a   Lim, J ^a   Kim, R K ^a   Shim, D ^a   Choi, J H ^a   Lee, S J ^a   Yu, J H ^b   Lee, J W ^b   Ahn, S H ^b   Shin, I ^a  

^a Hanyang University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DOXORUBICIN; EXTRACELLULAR MATRIX PROTEIN 1; GALECTIN 3; MUCIN 1; SCLEROPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; CTNNB1 PROTEIN, HUMAN; ECM1 PROTEIN, HUMAN; MUC1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BT 474 CELL LINE; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CYTOPLASM; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MDA MB 231 CELL LINE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SERUM; UPREGULATION; CELL MOTION; DRUG RESISTANCE; GENETICS; METASTASIS; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION;

BETA CATENIN; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MUCIN-1; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PROTEIN STABILITY;

EID: 84949626553     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.54     Document Type: Article

References (46)

1. Mathieu E, Meheus L, Raymackers J, Merregaert J. Characterization of the osteogenic stromal cell line MN7: identification of secreted MN7 proteins using two-dimensional polyacrylamide gel electrophoresis, western blotting, and microsequencing. J Bone Miner Res 1994; 9: 903-913.
2. Wang L, Yu J, Ni J, Xu XM, Wang J, Ning H et al. Extracellular matrix protein 1 (ECM1) is over-expressed in malignant epithelial tumors. Cancer Lett 2003; 200: 57-67.
3. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg 2005; 242: 353-361 discussion 361-353.
4. Lal G, Hashimi S, Smith BJ, Lynch CF, Zhang L, Robinson RA et al. Extracellular matrix 1 (ECM1) expression is a novel prognostic marker for poor long-term survival in breast cancer: a Hospital-based Cohort Study in Iowa. Ann Surg Oncol 2009; 16: 2280-2287.
5. Han Z, Ni J, Smits P, Underhill CB, Xie B, Chen Y et al. Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. FASEB J 2001; 15: 988-994.
6. Wu QW, She HQ, Liang J, Huang YF, Yang QM, Yang QL et al. Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer. BMC Cancer 2012; 12: 47.
7. Wu Q, Li X, Yang H, Lu C, You J, Zhang Z. Extracellular matrix protein 1 is correlated to carcinogenesis and lymphatic metastasis of human gastric cancer. World J Surg Oncol 2014; 12: 132.
8. Xiong GP, Zhang JX, Gu SP, Wu YB, Liu JF. Overexpression of ECM1 contributes to migration and invasion in cholangiocarcinoma cell. Neoplasma 2012; 59: 409-415.
9. Gu M, Guan J, Zhao L, Ni K, Li X, Han Z. Correlation of ECM1 expression level with the pathogenesis and metastasis of laryngeal carcinoma. Int J Clin Exp Pathol 2013; 6: 1132-1137.
10. Gilles C, Polette M, Birembaut P, Brunner N, Thompson EW. Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin Exp Metastasis 1997; 15: 519-526.
11. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996; 10: 2462-2477.
12. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 76-83.
13. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J et al. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002; 156: 299-313.
14. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
15. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331: 1559-1564.
16. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
17. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115.
18. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
19. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
20. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumorinitiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell stem Cell 2011; 9: 50-63.
21. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
22. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-480.
23. Neth P, Ries C, Karow M, Egea V, Ilmer M, Jochum M. The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion. Stem Cell Rev 2007; 3: 18-29.
24. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8: 97-106.
25. Lee KM, Nam K, Oh S, Lim J, Kim YP, Lee JW et al. ECM1 regulates cell proliferation and trastuzumab resistance through activation of EGF-signaling. Breast Cancer Res 2014; 16: 479.
26. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
27. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004; 114: 569-581.
28. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F et al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 2007; 26: 7445-7456.
29. Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H, Wirth T. NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett 2010; 295: 214-228.
30. Matsuda A, Suzuki Y, Honda G, Muramatsu S, Matsuzaki O, Nagano Y et al. Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene 2003; 22: 3307-3318.
31. Yamamoto M, Bharti A, Li Y, Kufe D. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem 1997; 272: 12492-12494.
32. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 2005; 65: 10413-10422.
33. Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED et al. The metastasisassociated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology 2006; 131: 1486-1500.
34. Sanchez-Tillo E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA 2011; 108: 19204-19209.
35. Tanida S, Mori Y, Ishida A, Akita K, Nakada H. Galectin-3 binds to MUC1-N-terminal domain and triggers recruitment of beta-catenin in MUC1-expressing mouse 3T3 cells. Biochim Biophys Acta 2014; 1840: 1790-1797.
36. Wen Y, Caffrey TC, Wheelock MJ, Johnson KR, Hollingsworth MA. Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol chem 2003; 278: 38029-38039.
37. Howe LR, Watanabe O, Leonard J, Brown AM. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res 2003; 63: 1906-1913.
38. Horvay K, Casagranda F, Gany A, Hime GR, Abud HE. Wnt signaling regulates Snai1 expression and cellular localization in the mouse intestinal epithelial stem cell niche. Stem Cells Dev 2011; 20: 737-745.
39. Sakai D, Tanaka Y, Endo Y, Osumi N, Okamoto H, Wakamatsu Y. Regulation of Slug transcription in embryonic ectoderm by beta-catenin-Lef/Tcf and BMP-Smad signaling. Dev Growth Differ 2005; 47: 471-482.
40. Kirstetter P, Anderson K, Porse BT, Jacobsen SE, Nerlov C. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol 2006; 7: 1048-1056.
41. Takao Y, Yokota T, Koide H. Beta-catenin up-regulates Nanog expression through interaction with Oct-3/4 in embryonic stem cells. Biochem Biophys Res Commun 2007; 353: 699-705.
42. Liu W, Hsu DK, Chen HY, Yang RY, Carraway KL 3rd, Isseroff RR et al. Galectin-3 regulates intracellular trafficking of EGFR through Alix and promotes keratinocyte migration. J Invest Dermatol 2012; 132: 2828-2837.
43. Zhao Q, Guo X, Nash GB, Stone PC, Hilkens J, Rhodes JM et al. Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res 2009; 69: 6799-6806.
44. Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011; 30: 1449-1459.
45. Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C et al. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene 2013; 33: 3422-31.
46. Alam M, Rajabi H, Ahmad R, Jin C, Kufe D. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget 2014; 5: 2622-34.